Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...
BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...
ULTOMIRIS™ (ravulizumab-cwvz) is the first and only long-acting C5 inhibitor administered every eight weeks that works by inhibiting the C5 protein in the terminal complement cascade, a part of the ...
When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. ULTOMIRIS is administered intravenously every eight weeks or, for ...
Cedric Francois, MD, PhD, Apellis Pharmaceuticals co-founder and CEO/President With its first FDA approval in hand for a complement inhibitor designed to treat paroxysmal nocturnal hemoglobinuria (PNH ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
A phase 3 study evaluating Ultomiris (ravulizumab-cwvz; Alexion) in hospitalized patients with coronavirus disease 2019 (COVID-19) is expected to begin in May. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback